XML 78 R113.htm IDEA: XBRL DOCUMENT
v2.4.0.8

Investments in Variable Interest Entities (Details Textual) (USD $) In Millions, unless otherwise specified | 12 Months Ended
--- | ---
Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 | Dec. 31, 2010
Investment in Variable Interest Entities (Textual) |  |  |  |
Percentage of operations of joint venture investments on financial statements |  |  | 100.00% |
Percentage of net income (loss) attributable to noncontrolling interests |  |  | 50.00% |
Investment in biotechnology companies that are determined to be unconsolidated variable interest entities | $ 5.5 | $ 9.4 |  |
Knopp |  |  |  |
Investment in Variable Interest Entities (Textual) |  |  |  |
Total upfront and reimbursement payment made to collaborative partner |  |  |  | 26.4
Purchase consideration for variable interest entities |  |  |  | 60.0
Research and development expense |  | 12.3 |  |
Percentage of funding for R&D cost required in support of the collaboration agreement | 100.00% |  |  |
Milestone payments made during period | 0 | 0 | 10.0 |
Neurimmune |  |  |  |
Investment in Variable Interest Entities (Textual) |  |  |  |
Percentage of funding for R&D cost required in support of the collaboration agreement | 100.00% |  |  |
Remaining potential development milestone payments and royalties on commercial sales under the terms of collaboration agreement | 345.0 |  |  |
Milestone payments made during period | $ 0 | $ 0 | $ 15.0 |
Common Class B | Knopp |  |  |  |
Investment in Variable Interest Entities (Textual) |  |  |  |
Purchase of common shares in variable interest entities |  |  |  | 30.00%

X
- Definition Investment in biotechnology companies that are determined to be unconsolidated variable interest entities. + References No definition available. + Details
Name: | biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Details
Name: | biib_InvestmentInVariableInterestEntitiesTextualAbstract
Namespace Prefix: | biib_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Milestone Payments Made During Period. + References No definition available. + Details
Name: | biib_MilestonePaymentsMadeDuringPeriod
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Net income loss attributable to noncontrolling interest percentage. + References No definition available. + Details
Name: | biib_NetIncomeLossAttributableToNoncontrollingInterestPercentage
Namespace Prefix: | biib_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of operations from joint-venture investments reflected in the consolidated financial statements. + References No definition available. + Details
Name: | biib_PercentageOfOperationsOfJointVentureInvestmentsReflectedInConsolidatedFinancialStatements
Namespace Prefix: | biib_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of cash paid to acquire stock of the entity. + References No definition available. + Details
Name: | biib_PurchaseConsiderationForVariableInterestEntities
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Purchase of common shares in variable interest entities. + References No definition available. + Details
Name: | biib_PurchaseOfCommonSharesInVariableInterestEntities
Namespace Prefix: | biib_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Expected total payments including upfront and milestone payments as well as the greater of an annual maintenance fee or usage-based royalty payments under the terms of collaboration agreement. + References No definition available. + Details
Name: | biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Research and development cost in support of the collaboration agreement. + References No definition available. + Details
Name: | biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement
Namespace Prefix: | biib_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Total upfront and reimbursement payment made to collaborative partner. + References No definition available. + Details
Name: | biib_UpfrontAndReimbursementPaymentMadeToCollaborativePartner
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration